Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion — Bloomberg · Left
Sino Biopharmaceutical signs cancer deal worth about $7 billion with Germany’s Boehringer — Salem Radio Network News · Right
Sino Biopharmaceutical signs cancer deal worth about $7 billion with Germany’s Boehringer — WTVB - Coldwater

Open True Mainstream to compare left, right, and center coverage